SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Non-small Cell Lung Cancer|Metastatic Triple-negative Breast Cancer
Interventions: BIOLOGICAL: ADV/HSV-tk|DRUG: Valacyclovir|RADIATION: SBRT|DRUG: Pembrolizumab
Sponsor: The Methodist Hospital Research Institute
Collaborators: Merck Sharp & Dohme LLC